Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acadesine - Ligand Pharmaceuticals

Next Previous
X
Search
Drug Profile

Acadesine - Ligand Pharmaceuticals

Alternative Names: Acadra; AICA riboside; ARA 100; Arasine; ATH 001; GP 1 110; Protara; SCH 900395

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AdvanCell; SICOR
  • Developer Advancell; Groupe Francophone des Myelodysplasies; Merck & Co; SICOR
  • Class Amides; Anti-ischaemics; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Antiplatelets; Antithrombotics; Imidazoles; Ribonucleosides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic lymphocytic leukaemia; Diabetes mellitus; Ischaemic heart disorders; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Thrombosis

Most Recent Events

  • 28 Jul 2021 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia (Second-line therapy or greater) in France, Belgium, Spain (IV) (Ligand Pharmaceuticals pipeline, July 2021)
  • 28 Jul 2021 Discontinued - Phase-I/II for Myelodysplastic syndromes (Recurrent, Treatment-resistant) in France (IV) (Ligand Pharmaceuticals pipeline, July 2021)
  • 28 Jul 2021 Discontinued - Preclinical for Mantle-cell lymphoma in Spain (IV) (Ligand Pharmaceuticals pipeline, July 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top